Table4.
Prognostic factors for overall survival of patient with SCRC
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P valuea | HR (95%CI) | P valuea | |
| Sex | ||||
| Female | 1 | (Reference) | ||
| Male | 1.30 (0.79–2.12) | 0.305 | ||
| EOCRC or LOCRC | ||||
| LOCRC | 1 | (Reference) | 1 | (Reference) |
| EOCRC | 0.55 (0.28–1.11) | 0.096 | 0.28 (0.13–0.62) | 0.002 |
| Family history of tumours | ||||
| No | 1 | (Reference) | 1 | (Reference) |
| Yes | 0.37 (0.09–1.49) | 0.160 | 0.57 (0.12–2.80) | 0.488 |
| BMI (kg/m2) | ||||
| 18.5 to 24 | 1 | (Reference) | ||
| < 18.5 | 0.97 (0.52–1.83) | 0.927 | ||
| ≥ 24 | 0.78 (0.47–1.28) | 0.320 | ||
| Haemoglobin (g/L) | ||||
| > 110 | 1 | (Reference) | 1 | (Reference) |
| ≤ 100 | 1.80 (1.17–2.77) | 0.007 | 1.75 (1.07–2.84) | 0.025 |
| Platelet counts (109/L) | ||||
| ≤ 300 | 1 | (Reference) | ||
| > 300 | 1.20 (0.76–1.89) | 0.431 | ||
| WBC (109/L) | ||||
| ≤ 10 | 1 | (Reference) | ||
| > 10 | 1.19 (0.60–2.38) | 0.622 | ||
| CEA (ng/mL) | ||||
| ≤ 10 | 1 | (Reference) | 1 | (Reference) |
| > 10 | 2.65 (1.72–4.09) | < 0.001 | 1.38 (0.82–2.31) | 0.220 |
| CA199 (kU/L) | ||||
| ≤ 27 | 1 | (Reference) | 1 | (Reference) |
| > 27 | 2.24 (1.44–3.47) | < 0.001 | 1.04 (0.61–1.78) | 0.884 |
| CA125 (kU/L) | ||||
| ≤ 35 | 1 | (Reference) | 1 | (Reference) |
| > 35 | 5.88 (3.49–9.91) | < 0.001 | 4.19 (2.23–7.85) | < 0.001 |
| CA153 (kU/L) | ||||
| ≤ 25 | 1 | (Reference) | 1 | (Reference) |
| > 25 | 5.78 (1.79–18.69) | 0.003 | 3.65 (0.98–13.57) | 0.054 |
| AFP (ng/mL) | ||||
| ≤ 7 | 1 | (Reference) | ||
| > 7 | 0.68 (0.22–2.16) | 0.516 | ||
| Type of ascites | ||||
| No | 1 | (Reference) | 1 | (Reference) |
| Serous | 1.28 (0.62–2.66) | 0.505 | 0.55 (0.24–1.24) | 0.150 |
| Bloody | 6.78 (2.12–21.74) | 0.001 | 3.53 (0.87–14.27) | 0.077 |
| Tumor location | ||||
| Right colon | 1 | (Reference) | ||
| Left colon | 0.68 (0.35–1.32) | 0.257 | ||
| Rectum | 0.77 (0.42–1.41) | 0.398 | ||
| Multiple segment | 0.68 (0.38–1.23) | 0.200 | ||
| Radical or palliative surgery | ||||
| Radical | 1 | (Reference) | 1 | (Reference) |
| Palliative | 6.45 (4.17–9.96) | < 0.001 | 2.87 (1.17–7.02) | 0.021 |
| (y)pTNM staging | ||||
| 0–I | 1 | (Reference) | 1 | (Reference) |
| II | 3.13 (0.72–13.6) | 0.129 | 2.77 (0.63–12.22) | 0.178 |
| III | 5.32 (1.26–22.53) | 0.023 | 5.34 (1.24–22.98) | 0.025 |
| IV | 17.27 (4.18–71.47) | < 0.001 | 5.89 (1.16–29.77) | 0.032 |
| Number of retrieved lymph nodes | ||||
| < 12 | 1 | (Reference) | 1 | (Reference) |
| ≥ 12 | 1.82 (0.94–3.53) | 0.075 | 1.55 (0.75–3.22) | 0.240 |
| Gross classification | ||||
| Mass type | 1 | (Reference) | ||
| Infiltration type | 1.75 (0.53–5.71) | 0.355 | ||
| Ulceration type | 0.86 (0.55–1.34) | 0.499 | ||
| Histological type | ||||
| Classical adenocarcinoma | 1 | (Reference) | ||
| Mucinous adenocarcinoma | 0.64 (0.26–1.57) | 0.328 | ||
| Signet ring cell carcinoma | 0 (0-Inf) | 0.994 | ||
| Differentiation grade | ||||
| Well differentiated | 1 | (Reference) | ||
| Moderately differentiated | 1.15 (0.65–2.02) | 0.634 | ||
| Poorly differentiated | 1.09 (0.53–2.23) | 0.824 | ||
| Vessel invasion | ||||
| Negative | 1 | (Reference) | 1 | (Reference) |
| Positive | 1.82 (1.11–2.99) | 0.018 | 1.09 (0.60–1.98) | 0.780 |
| Neural invasion | ||||
| Negative | 1 | (Reference) | 1 | (Reference) |
| Positive | 2.37 (1.45–3.87) | 0.001 | 1.32 (0.71–2.44) | 0.378 |
| Ki67 expression | ||||
| Low | 1 | (Reference) | 1 | (Reference) |
| Moderate | 0.64 (0.28–1.43) | 0.275 | 1.10 (0.45–2.66) | 0.833 |
| High | 0.58 (0.30–1.13) | 0.111 | 1.00 (0.47–2.13) | 0.999 |
| MMR status | ||||
| pMMR | 1 | (Reference) | 1 | (Reference) |
| dMMR | 0.48 (0.22–1.04) | 0.063 | 0.77 (0.32–1.83) | 0.551 |
HR hazard ratio, CI confidence interval. aThe bolded P value was statistically significant (P < 0.05)